Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a change in the notional interest of a Person Discharging Managerial Responsibilities (PDMR) in the company's ordinary shares.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Date | July 14, 2016 |
| Instrument | Ordinary Shares (ISIN: GB0009252882) |
| Transaction Price | £16.285 |
| Aggregated Volume | 3,591.951 shares |
Material Changes
The filing reports an increase in the notional interest of Mr. R G Connor, President of Global Manufacturing & Supply. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Performance Share Plan. There are no reported material changes to the company's operations or financial position in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a routine disclosure of a PDMR transaction.
Key Facts for Investor Verification
- Executive Action: Mr. R G Connor increased his notional shareholding via dividend re-investment.
- Transaction Volume: A total of 3,591.951 shares were acquired at a price of £16.285 per share.
- Plan Context: The transaction occurred under the 2009 Performance Share Plan.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial performance.